Friday, July 1, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home Coronavirus

Incidence and outcomes of breakthrough SARS-CoV-2 infections in vaccinated chronic liver disease patients

by Medical Finance
in Coronavirus
Incidence and outcomes of breakthrough SARS-CoV-2 infections in vaccinated chronic liver disease patients
9
SHARES
99
VIEWS
Share on FacebookShare on Twitter

The development of safe and effective vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has significantly altered the course of the coronavirus disease 2019 (COVID-19) pandemic. Both clinical trials and real-world evidence have demonstrated that current COVID-19 vaccines are extremely effective, particularly in reducing the risk of severe disease.

shutterstock 1895079868Study: Outcomes of SARS-CoV-2 Infection in Patients with Chronic Liver Disease and Cirrhosis: A National COVID Cohort Collaborative Study. Image Credit: TSViPhoto / Shutterstock.com

Background

Despite the advantages associated with current COVID-19 vaccines, individuals with chronic liver disease (CLD) have well-documented immunological dysfunction, as well as reduced vaccination responses. In fact, previous studies have shown that 22.2% of CLD patients who received whole virion subunit vaccines did not exhibit any antibody responses, whereas 24.0% of those who received messenger ribonucleic acid-based (mRNA) SARS-CoV-2 vaccines had inadequate antibody responses.

Previous studies have also shown that patients with cirrhosis who become infected with SARS-CoV-2 are also at a greater risk of morbidity and mortality. Taken together, these findings support the development of improved SARS-CoV-2 immunization regimens in CLD patients.

A new study published on the medRxiv* preprint server evaluates the incidence and consequences of breakthrough SARS-CoV-2 infections in vaccinated CLD patients with cirrhosis as compared to CLD patients without cirrhosis. To describe outcomes in vaccinated CLD patients, the researchers used the National COVID Cohort Collaborative (N3C), a dataset of 10.7 million individuals, of whom 0.9 million have vaccination data.

About the study

The researchers used the National COVID Cohort Collaborative (N3C), which is a dataset of 10.7 million individuals, of whom 0.9 million have vaccination data. Within the N3C dataset, the researchers identified 278,457 CLD patients, with or without cirrhosis, who underwent SARS-CoV-2 testing.

Both vaccinated and unvaccinated CLD patients were included in the current study. Patients who had received two mRNA vaccines from either Pfizer-BioNTech (BNT162b2) and Moderna (mRNA-1273), as well as those who received one dose of the Johnson & Johnson viral vector vaccine (JNJ-784336725) were considered vaccinated in the current study. However, a fully vaccinated description was only provided after 14 days of the patient receiving either two doses of an mRNA vaccine or one dose of the viral vector vaccine.

The primary outcomes assessed in the current study included SARS-CoV-2 breakthrough infection rates, as well as all-cause mortality at 30 days following the SARS-CoV-2 infection. Notably, a breakthrough infection was defined as a SARS-CoV-2 infection in both partially vaccinated and fully vaccinated patients without a prior history of COVID-19.

The researchers were also interested in assessing hospitalization and mechanical ventilation data on CLD patients within 30 days of testing positive for SARS-CoV-2.

Study findings

A total of 278,457 CLD patients were included in the current study, of which 43,079 (15%) were vaccinated against COVID-19 and 235,378 (85%) were unvaccinated. Notably, 32,838 (76%) of the vaccinated CLD patients did not have cirrhosis, while 10,441 (24%) did.

Of the 27,235 fully vaccinated CLD patients without cirrhosis and 8,218 fully vaccinated CLD patients with cirrhosis, the estimated incidence rates for breakthrough infections were 5.6 and 5.1 per 1,000 person-months, respectively.

The presence of cirrhosis among vaccinated CLD patients did not appear to increase the patient’s risk of breakthrough SARS-CoV-2 infection. Notably, CLD patients who were fully vaccinated reported a 73% reduced risk of breakthrough infection as compared to those with partial vaccination status.

Upon comparison of the efficacy of specific COVID-19 vaccines in this patient population, those who were fully vaccinated with mRNA-1273 had an 18% reduced risk of breakthrough infection as compared to those fully vaccinated with BNT162b2. However, CLD patients who received the Johnson & Johnson vaccine were at a 54% greater risk of breakthrough infection as compared to BNT162b2 recipients. Sex, age, and race/ethnicity did not have an apparent effect on breakthrough infection risk.

Vaccinated CLD patients with cirrhosis who experienced a breakthrough SARS-CoV-2 infection had reduced hospitalization, ventilation, and death rates within 30 days as compared to unvaccinated CLD patients. While CLD patients with cirrhosis and breakthrough infection may still experience major consequences, complete vaccination was linked to a 66% reduction in the chance of death from any cause within 30 days.

F2.large 5130-day outcomes of SARS-CoV-2 infection in unvaccinated and vaccinated CLD patients with cirrhosis.

*Important notice

medRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

Small cluster of neurons in the brain stem found to coordinate vocalization with breathing

Research finds quick recovery of heart function in children with COVID-19-related MIS-C

by Medical Finance
June 30, 2022
0

Heart function recovery returned within three months in children who developed COVID-19-related multisystem inflammatory syndrome (MIS-C), according to new research...

Study: The BNT162b2 mRNA SARS-CoV-2 vaccine induces transient afucosylated IgG1 in naive but not antigen-experienced vaccinees. Image Credit: BaLL LunLa/Shutterstock

mRNA COVID-19 vaccine shown to induce afucosylated antibodies in individuals without prior SARS-CoV-2 exposure

by Medical Finance
June 30, 2022
0

Scientists from the Netherlands and Germany have recently investigated the glycosylation of anti-spike IgG antibodies in response to the mRNA-based...

Acute hepatitis and adenovirus infection among pediatric patients in Alabama

Acute hepatitis and adenovirus infection among pediatric patients in Alabama

by Medical Finance
June 30, 2022
0

A new study published by the Centers for Disease Control and Prevention (CDC) today, "Acute Hepatitis and Adenovirus Infection Among...

Study: Post-acute neurological consequences of COVID-19: an unequal burden. Image Credit: CHOONGKY/Shutterstock

Study shows inequalities in addressing post-acute neurological manifestations of COVID-19

by Medical Finance
June 30, 2022
0

In a recent article published in the Nature Medicine journal, researchers explored the inequities in understanding and addressing the neurological...

Study: SARS-CoV-2-specific T cells associate with reduced lung function and inflammation in pulmonary post-acute sequalae of SARS-CoV-2. Image Credit: AGCuesta/Shutterstock

Frequency and function of SARS-CoV-2-specific T cells in individuals with pulmonary PASC

by Medical Finance
June 30, 2022
0

In a recent study posted to the bioRxiv* preprint server, researchers examined patients with pulmonary post-acute sequelae (PASC) of severe...

Study: Distinct miRNAs associated with various clinical presentations of SARS-CoV-2 infection. Image Credit: ART-ur / Shutterstock

miRNAs associated with varying clinical presentations of SARS-CoV-2

by Medical Finance
July 1, 2022
0

A recent article published in the journal iSCIENCE demonstrated different micro ribonucleic acids (miRNAs) linked with various presentations of the severe acute...

Next Post
New tool could help detect geographical hotspots for mental health problems caused by COVID

A health-heavy State of the Union

Study: Variability in transmission risk of SARS-CoV-2 in close contact settings: A contact tracing study in Shandong Province, China. Image Credit: elenabsl/Shutterstock

Contact tracing data from the first COVID-19 pandemic wave in Shandong Province, China

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • Two cell embryo Mitosis under microscope 3D illustration Illustration Andrii Vodolazhskyi M1 4bb73c51d46c449285a21e8af28684d6 620x480
    UW Medicine scientists contribute to the publication of first complete, gapless genome sequence
  • DNA Genetics 620x480
    Accurate detection of specific genomic disorders made possible by nanopore sequencing
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply